Wedbush Reiterates “Outperform” Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “outperform” rating restated by Wedbush in a report released on Thursday, Benzinga reports. They presently have a $45.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 269.16% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. Roth Capital reiterated a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Wall Street Zen upgraded shares of Immunic from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, August 26th. Finally, Wolfe Research assumed coverage on shares of Immunic in a report on Friday, May 22nd. They set an “outperform” rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $47.25.

Immunic Stock Down 4.3%

IMUX stock opened at $12.19 on Thursday. The business has a 50 day moving average of $14.81 and a 200 day moving average of $13.07. The firm has a market cap of $166.27 million, a PE ratio of -2.78 and a beta of 1.41. Immunic has a twelve month low of $5.06 and a twelve month high of $17.43.

Immunic (NASDAQ:IMUX) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.36. On average, research analysts expect that Immunic will post -3.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several large investors have recently bought and sold shares of IMUX. CTC Alternative Strategies Ltd. purchased a new position in Immunic in the 1st quarter worth about $27,000. ADAR1 Capital Management LLC purchased a new stake in shares of Immunic during the 1st quarter valued at about $33,000. Qube Research & Technologies Ltd bought a new stake in shares of Immunic in the third quarter worth approximately $29,000. Focus Partners Wealth grew its stake in shares of Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after acquiring an additional 39,063 shares during the period. Finally, Two Sigma Investments LP purchased a new position in shares of Immunic during the third quarter valued at approximately $52,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.